https://www.bioworld.com/rss en-us Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s disease, diabetic neuropathy, glaucoma, viral infections, chemotherapy-induced peripheral neuropathy and stroke, among others. http://www.bioworld.com/articles/733081 Fri, 31 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733081-tuojie-biotech-shanghai-synthesizes-new-sarm1-inhibitors Apex Bioscience Inc. has presented phosphodiesterase PDE4 and cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A; PDE5) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease (COPD), heart failure, hepatic fibrosis, inflammatory bowel disease, rheumatoid arthritis, idiopathic pulmonary fibrosis and Alzheimer’s disease, among others. http://www.bioworld.com/articles/733080 Fri, 31 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733080-apex-bioscience-discovers-new-pde4-and-pde5-inhibitors Tahrget Therapeutics Ltd. has patented substituted adefovir compounds acting as viral DNA polymerase inhibitors that are potentially useful for the treatment of Epstein-Barr virus infections. http://www.bioworld.com/articles/733079 Fri, 31 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733079-tahrget-therapeutics-discloses-new-viral-dna-polymerase-inhibitors Sunrock Biopharma SL has disclosed antibody-drug conjugates (ADCs) comprising an antibody targeting C-C chemokine receptor type 9 (CCR9) linked to camptothecin derivatives through a linker found to be potentially useful for the treatment of cancer. http://www.bioworld.com/articles/733078 Fri, 31 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733078-sunrock-biopharma-reports-new-ccr9-targeting-adcs Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of cancer, autoimmune and metabolic disease, eye, dermatological, respiratory, cardiovascular and renal disorders, among others. http://www.bioworld.com/articles/733077 Fri, 31 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733077-sitala-bio-identifies-new-complement-factor-b-inhibitors Shanghai Zheye Biotechnology LLC has prepared and tested new phenylpropionic acid derivatives acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors that are potentially useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis. http://www.bioworld.com/articles/733063 Thu, 30 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733063-shanghai-zheye-biotechnology-synthesizes-new-apoa-apob-interaction-inhibitors Beta Pharma Inc. has disclosed antibody-drug conjugates consisting of humanized monoclonal antibody trastuzumab targeting receptor tyrosine-protein kinase erbB-2 (erbB2; HER2) covalently linked to cytotoxic drug through a cleavable linker reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/733062 Thu, 30 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733062-beta-pharma-identifies-new-her2-targeting-adcs Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported GTPase KRAS (G12D mutant) inhibitors found to be useful for the treatment of non-small-cell lung and pancreatic cancer. http://www.bioworld.com/articles/733061 Thu, 30 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733061-shandong-simcere-medgenn-bio-pharmaceutical-discloses-new-kras-g12d-inhibitors Insilico Medicine Inc. has patented cyclin-dependent kinase (CDK) inhibitors, particularly CDK2/cyclin E1 and/or and CDK4/cyclin D3, reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/733060 Thu, 30 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733060-insilico-medicine-discovers-new-cdk-inhibitors Shanghai Qilu Pharmaceutical Research Development Centre Ltd. has identified soluble guanylate cyclase (sGC) activators that are potentially useful for the treatment of chronic kidney disease and diabetic nephropathy. http://www.bioworld.com/articles/733059 Thu, 30 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733059-shanghai-qilu-pharmaceutical-research-patents-new-sgc-activators Hainan Shibeikang Biological Medical Technology Co. Ltd. has identified new amino halogenated benzyl derivatives acting as voltage-gated sodium channel blockers potentially useful for the treatment of inflammatory disorders. http://www.bioworld.com/articles/733015 Wed, 29 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733015-hainan-shibeikang-biological-medical-technology-reports-new-voltage-gated-sodium-channel-blockers Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has patented new salts of complement factor B (CFB) inhibitors potentially useful for the treatment of diabetic nephropathy, IgA nephropathy, paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, atypical hemolytic uremic syndrome and membranous nephropathy. http://www.bioworld.com/articles/733014 Wed, 29 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733014-shanghai-fosun-pharmaceutical-industry-development-discovers-new-cfb-inhibitors Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor agonists potentially useful for the treatment of schizophrenia, depression, Parkinson’s and Alzheimer’s disease. http://www.bioworld.com/articles/733013 Wed, 29 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733013-jingxin-discloses-new-muscarinic-and-sigma-receptor-agonists Beijing Danatlas Pharmaceutical Technology Co. Ltd. has discovered new peroxisome proliferator-activated receptor γ (PPARγ) modulators potentially useful for the treatment of bladder cancer. http://www.bioworld.com/articles/733012 Wed, 29 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733012-beijing-danatlas-pharmaceutical-technology-identifies-new-ppar-modulators Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Tianjin Hengrui Medicine Co. Ltd. have disclosed new fibroblast activation protein-α (FAPα) inhibitors covalently linked to radiolabeled chelating agents through a linker potentially useful for the treatment of cancer, inflammatory, cardiovascular disorders and more. http://www.bioworld.com/articles/733011 Wed, 29 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/733011-hengrui-patents-new-fap-inhibitors Boston Scientific Corp. came out the all-around winner July 27 when the U.S. Court of Appeals for the Federal Circuit reversed a jury verdict that found the med-tech company’s drug-eluting coronary stent systems infringed a University of Texas System patent. http://www.bioworld.com/articles/732931 Tue, 28 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732931-no-infringement-here-fed-circuit-says-in-ruling-for-boston-sci Boston Scientific signage Credit: Boston Scientific Corp. Shanghai Jeyou Pharmaceutical Co. Ltd. has discovered new ATP-dependent RNA helicase A (DHX9) inhibitors potentially useful for the treatment of cancer, viral infection and autoimmune disease. http://www.bioworld.com/articles/732991 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732991-shanghai-jeyou-pharmaceutical-identifies-new-dhx9-inhibitors Shanghai Escugen Biotechnology Co. Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic drug potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732990 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732990-shanghai-escugen-biotechnology-reports-new-trop2-targeting-adcs Suven Life Sciences Ltd. has reported new muscarinic acetylcholine M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of schizophrenia, Alzheimer’s disease, Parkinson’s disease, depression, bipolar disorders, Huntington’s disease, attention deficit hyperactivity disorder and pain, among others. http://www.bioworld.com/articles/732989 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732989-suven-life-sciences-divulges-new-muscarinic-m4-receptor-pams Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has patented new trichloroethanol derivatives potentially useful for the treatment of sleep disorders, anxiety disorders and convulsions. http://www.bioworld.com/articles/732988 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732988-chengdu-shibeikang-biological-medicine-discovers-new-trichloroethanol-derivatives A joint China State Institute of Pharmaceutical Industry and Shanghai Institute of Pharmaceutical Industry Co. Ltd. patent divulges new mitochondrial pyruvate carrier (MPC) inhibitors potentially useful for the treatment of alopecia, diabetes, metabolic and inflammatory disorders. http://www.bioworld.com/articles/732987 Tue, 28 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732987-china-state-institute-and-shanghai-institute-of-pharmaceutical-industry-synthesize-new-mpc-inhibitors Exeliris Co. Ltd. and Lin Gang Laboratory have reported phosphatidylinositol 3-kinase α (PI3Kα) inhibitors that are potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732971 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732971-exeliris-and-lin-gang-laboratory-identify-new-pi3k-inhibitors Fortvita Biologics Inc. and Innovent Biologics (Hangzhou) Co. Ltd. have patented bispecific antibody-drug conjugates (ADCs) comprising a bispecific humanized monoclonal antibody targeting EGFR and hepatocyte growth factor receptors (HGFR; MET) linked to cytotoxic drugs reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732970 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732970-fortvita-biologics-and-innovent-biologics-disclose-new-bispecific-adcs-targeting-egfr-and-hgfr Alzecure Pharma AB has disclosed UDP-glucuronosyltransferase A1 (UGT1A1; UDPGT 1-1) inhibitors that are potentially useful for the treatment of Lewy body dementia, Creutzfeldt-Jakob disease, frontotemporal dementia, amyotrophic lateral sclerosis, traumatic brain injury, and Parkinson's, Alzheimer's and Huntington's disease, among others. http://www.bioworld.com/articles/732969 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732969-alzecure-pharma-patents-new-ugt1a1-inhibitors Innovstone Therapeutics Ltd. has synthesized cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors found to be potentially useful for the treatment of autoimmune diseases and cancer. http://www.bioworld.com/articles/732968 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732968-innovstone-therapeutics-discloses-new-cathepsin-c-inhibitors Betta Pharmaceuticals Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds consisting of a Von Hippel-Lindau-binding moiety coupled to a GTPase KRAS-targeting moiety through a linker acting as KRAS degradation inducers. http://www.bioworld.com/articles/732967 Mon, 27 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732967-betta-pharmaceuticals-reports-new-kras-degradation-inducers Bioray Pharmaceutical Co. Ltd. has prepared and tested new antibody-drug conjugates consisting of antibodies covalently linked to payloads. They are reported to be potentially useful for the treatment of cancer, infections, inflammatory and immunological disorders. http://www.bioworld.com/articles/732910 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732910-antibody-drug-conjugates-reported-in-bioray-pharmaceutical-patent Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has patented new gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of metabolic diseases. http://www.bioworld.com/articles/732909 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732909-chia-tai-tianqing-pharmaceutical-discovers-new-gipr-antagonists Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug potentially useful for the treatment of colorectal cancer. http://www.bioworld.com/articles/732908 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732908-hengrui-synthesizes-new-adcs-targeting-ceacam5 Zonsen Peplib Biotech Inc. has synthesized new peptide-drug conjugates comprising a glypican-3 (GPC3)-targeting peptide covalently linked to a payload potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732907 Fri, 24 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732907-zonsen-peplib-biotech-discloses-new-gpc3-targeting-peptide-drug-conjugates